XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 06, 2016
Jan. 18, 2018
Sep. 30, 2017
Jul. 24, 2017
Jan. 26, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Jun. 27, 2018
May 09, 2018
Sep. 25, 2017
May 26, 2017
Related Parties Transactions (Textual)                            
Amount received from BriVision           $ 4,020,100   $ 4,020,100   $ 4,229,320        
Outstanding loan               793,000   950,000        
Accrued interest               8,297   17,460        
Interest expenses           38,186 $ 28,500 71,831 $ 47,500          
Additional paid-in capital           13,901,582   13,901,582   13,805,936        
Monthly base rent               5,000            
Rent expenses               0 30,000          
Related party transactions, description     Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of June 30, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 15, 2019.                      
Unsecured convertible promissory note [Member]                            
Related Parties Transactions (Textual)                            
Accrued interest               3,566            
Aggregate principal amount                     $ 250,000 $ 300,000    
Chairman [Member]                            
Related Parties Transactions (Textual)                            
Aggregate working capital               $ 100   $ 100        
Interest rate percentage               0.00%   0.00%        
Collaborative Arrangement [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision       $ 3,000,000   100,000,000   $ 100,000,000            
Common stock new issues $ 900,000     $ 3,000,000                    
Due to BioFirst                         $ 3,000,000  
Yuangene Corporation [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision           53,000   53,000   $ 3,000        
Outstanding loan               50,000   0        
Accrued interest               2,696   0        
Interest expenses               2,696 0          
Aggregate working capital   $ 50,000           $ 3,000   $ 3,000        
Interest rate percentage               0.00%   0.00%        
Related party transactions, description   Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 19, 2019.                        
Loan Agreement [Member]                            
Related Parties Transactions (Textual)                            
Total commitment         $ 950,000                  
Loan maturity date         Feb. 01, 2018                  
Loan agreement, description         The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.                  
Asiangene Corporation [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision           160,000   $ 160,000   $ 160,000        
Outstanding loan               160,000   160,000        
Accrued interest               4,787   0        
Interest expenses               8,732 0          
BioLite [Member]                            
Related Parties Transactions (Textual)                            
Aggregate working capital               $ (2,135)   $ 109,220        
Interest rate percentage               0.00%   0.00%        
Co-Dev Agreement [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision           450,000   $ 450,000   $ 450,000       $ 3,000,000
Common stock new issues               2,550,000   2,550,000        
Additional paid-in capital     $ 3,000,000                      
BioFirst Corporation [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision           $ 3,807,000   3,807,000   3,957,000        
Interest expenses               56,837 $ 47,500          
Aggregate working capital               $ 14,000   $ 7,000        
Interest rate percentage               0.00%   0.00%        
BioFirst (Australia) Pty Ltd. [Member]                            
Related Parties Transactions (Textual)                            
Aggregate working capital               $ 40,000            
Interest rate percentage               0.00%